Lista de obras - Francesca Lavatelli - Dominio Público Uruguay

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

artículo científico publicado en 2014

A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.

artículo científico publicado en 2011

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

artículo científico publicado en 2012

A practical approach to the diagnosis of systemic amyloidoses.

artículo científico publicado en 2015

A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli

artículo científico publicado en 2013

A workflow management system for the biological samples exchange within the amyloidosis network ⬇️

artículo científico publicado el 1 de junio de 2011

AMICA: an electronic patient record specifically designed for an amyloidosis network ⬇️

artículo científico publicado el 1 de junio de 2011

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis

scientific article published on 04 February 2019

Advances in proteomic study of cardiac amyloidosis: progress and potential.

artículo científico publicado en 2016

Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.

artículo científico publicado en 2013

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

artículo científico publicado en 2008

Biochemical markers in early diagnosis and management of systemic amyloidoses.

artículo científico publicado en 2014

Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis.

artículo científico publicado en 2012

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

artículo científico publicado en 2006

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays

artículo científico publicado en 2017

Clinical proteomics for diagnosis and typing of systemic amyloidoses.

artículo científico

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity

artículo científico publicado en 2017

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient

artículo científico publicado en 2019

How do we improve treatments for patients with amyloidosis using proteomics?

artículo científico publicado en 2017

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

artículo científico publicado en 2017

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

artículo científico publicado en 2009

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.

artículo científico publicado en 2016

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

artículo científico publicado en 2013

Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits ⬇️

artículo científico publicado el 1 de junio de 2011

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

artículo científico publicado en 2014

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis

artículo científico publicado en 2011

Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations

artículo científico publicado en 2019

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

artículo científico publicado en 2015

Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.

artículo científico

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

artículo científico publicado en 2011

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

artículo científico publicado en 2013

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

artículo científico publicado en 2017

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

artículo científico publicado en 2017

Prognostication of survival and progression to dialysis in AA amyloidosis

artículo científico publicado en 2017

Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations ⬇️

artículo científico publicado el 1 de junio de 2011

Proteomic typing of amyloid deposits in systemic amyloidoses.

artículo científico publicado en 2011

Proteomics in protein misfolding diseases.

artículo científico publicado en 2009

Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing

artículo científico publicado en 2018

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells

artículo científico publicado en 2017

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

artículo científico publicado en 2011

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

artículo científico publicado en 2011

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

artículo científico publicado en 2017

Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses.

artículo científico publicado en 2013

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

artículo científico publicado en 2019

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

artículo científico publicado en 2013

Systemic amyloidoses and proteomics: The state of the art.

artículo científico publicado en 2016

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

artículo científico publicado en 2004

The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis

scientific article published on 01 January 2019

The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis

artículo científico publicado en 2016

Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.

artículo científico publicado en 2011

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

scientific article published on 01 July 2007

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis

artículo científico publicado en 2017

Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration

artículo científico publicado en 2019

Lista de obras de Francesca Lavatelli

A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis

A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum.

A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis.

A practical approach to the diagnosis of systemic amyloidoses.

A strategy for synthesis of pathogenic human immunoglobulin free light chains in E. coli

A workflow management system for the biological samples exchange within the amyloidosis network ⬇️

AMICA: an electronic patient record specifically designed for an amyloidosis network ⬇️

ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis

Advances in proteomic study of cardiac amyloidosis: progress and potential.

Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis.

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

Biochemical markers in early diagnosis and management of systemic amyloidoses.

Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis.

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays

Clinical proteomics for diagnosis and typing of systemic amyloidoses.

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient

How do we improve treatments for patients with amyloidosis using proteomics?

Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis.

Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study.

Malnutrition at diagnosis predicts mortality in patients with systemic immunoglobulin light-chain amyloidosis independently of cardiac stage and response to treatment.

Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits ⬇️

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis

Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations

Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis.

Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis.

Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis.

Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome.

Patterns of relapse after upfront bortezomib therapy in AL amyloidosis

Prognostication of survival and progression to dialysis in AA amyloidosis

Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations ⬇️

Proteomic typing of amyloid deposits in systemic amyloidoses.

Proteomics in protein misfolding diseases.

Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells

Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue.

Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide

Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response

Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses.

Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients

Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity

Systemic amyloidoses and proteomics: The state of the art.

The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).

The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis

The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis

Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.

Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis

Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis

Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration